stockrow
Friday 6 November 2026
Export STAA’s income statement to Excel — free account
STAAR Surgical Company
STAA Healthcare Medical Instruments & Supplies
STAAR Surgical Company’s revenue for fiscal 2025 (year ended December 2025) was $239.4 million, down 23.7% from fiscal 2024.
- Revenue
- −12.0%
- EPS
- −38.9%
- Free cash flow
- +1,378.7%
Quarter to September 2026, against a year earlier
25.51
1.21
−4.53%
Follow STAA
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 409.86 | 0.00 |
P/S ratio |
4.78 | 3.21 | 4.25 | 3.48 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 64.33 | |
P/Operating CF |
(292.42) | (43.02) | 73.32 | 41.84 | |
P/B ratio |
3.33 | 2.65 | 3.95 | 3.04 | |
Price to Tangible BV |
3.34 | 2.66 | 3.97 | 3.05 | |
EV/Sales |
4.13 | 2.76 | 3.81 | 2.95 | |
EV/EBITDA |
0.00 | 0.00 | 55.79 | 41.73 | |
EV/Operating CF |
(28.91) | (15.95) | (397.73) | 45.22 | |
EV/FCF |
(24.65) | (14.54) | (189.32) | 54.47 | |
Quick Ratio |
3.47 | 4.02 | 3.81 | 3.88 | |
Current Ratio |
4.55 | 5.12 | 4.66 | 4.68 | |
Net Debt/EBITDA |
7.54 | (13.33) | (13.53) | 0.00 | |
Debt/Assets |
7.19% | 6.91% | 0.00% | 0.00% | |
Debt/Equity |
0.09 | 0.09 | 0.00 | 0.00 | |
Asset Turnover |
0.50 | 0.64 | 0.74 | 0.70 | |
Operating CF/Net income |
0.21 | (4.17) | 2.44 | 4.90 | |
Capex/Depreciation |
(0.74) | (0.22) | (0.15) | 0.00 | |
Research and Development Expense of Revenue |
15.99% | 10.61% | 10.63% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
78.60% | 44.41% | 53.12% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
14.90% | 5.16% | 7.01% | 6.61% | |
Graham Net Nets |
0.18 | 0.23 | 0.16 | 0.21 | |
Graham Number |
0.00 | 0.00 | 3.38 | 0.00 | |
Earnings Yield |
(7.06%) | (2.30%) | 0.24% | 0.00% | |
Free Cash Flow Yield |
(3.51%) | (5.90%) | (0.47%) | 1.55% | |
Revenue per Share |
1.17 | 1.87 | 1.86 | 1.65 | |
Operating CF per Share |
(0.08) | (0.43) | 0.39 | 0.54 | |
Capex per Share |
(0.03) | (0.01) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(0.11) | (0.44) | 0.38 | 0.52 | |
Cash per Share |
3.78 | 3.28 | 3.61 | 4.08 | |
Shareholders Equity per Share |
6.94 | 7.06 | 7.26 | 7.44 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.94 | 7.06 | 7.26 | 7.44 | |
Free Cash Flow |
(5.59) | (22.14) | 19.20 | 26.38 | |
Working Capital |
243.04 | 251.40 | 268.96 | 277.89 | |
Capital Expenditures |
(1.68) | (0.44) | (0.49) | (0.93) | |
Net Current Asset Value |
204.05 | 213.65 | 232.55 | 244.40 | |
EV/EBIT |
0.00 | 0.00 | 94.19 | 1,380.21 | |
Capex to Sales |
0.03 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 105.13 | 1,630.18 | |
| Other line items | |||||
Average Receivables |
63.98 | 60.56 | 66.46 | 73.32 | |
Average Payables |
14.14 | 10.08 | 12.91 | 11.71 | |
Average Inventory |
49.40 | 48.96 | 49.97 | 49.16 | |
Average Assets |
480.60 | 454.24 | 456.49 | 470.76 | |
Average Common Equity |
370.76 | 351.17 | 350.99 | 364.95 |
Columns are period end dates · fundamentals updated 4 Nov 2026